ALL DISPATCHES

THE DAILY DISPATCH · NOVEMBER 12, 2026

AI control advances; biology trials keep expanding

Across the landscape, the cure race continues to compound: there are 21,500 active gene, cell, mRNA and SI trials worldwide, with 9 new Cure research signals added in the last 24 hours. In the parallel AI/capital phase transition, a notable Wire shift showed an OpenAI model making a virtual duck-cat robot demo teachable—an early indicator that control of action is moving toward models, not just tools. At the same time, other signals warn that the same connectivity and data pathways that power progress also expand the capture surface: hacked fridges and a union blocking a $10 million Google-linked data sale both point to who controls downstream reality. The stakes are human and immediate—precision medicine advances while power over systems, data, and action accelerates—so the practical watch is whether today’s control-of-action demonstrations translate into accountable, medically-relevant deployment under enforceable governance. The window is still open.

THE SIGNAL

An OpenAI model was used to make a virtual duck-cat robot demo teachable.

THE STAKES

Gains in action-control models can speed the next platform shift, but whoever sets access and governance can decide whether breakthroughs serve public health or capture.

THE WINDOW

Watch the 55 new Wire signals for governance-and-deployment tests, and track whether the 9 new Cure items stay tied to translational outcomes across the expanding trial base.

21,500Trials on clinical registries
Preserved copy

An independent copy of this edition is kept by the Internet Archive: https://web.archive.org/web/20261116110927/https://negativeresistance.com/dispatch/2026-11-12

Permalink: https://negativeresistance.com/dispatch/2026-11-12 · How this site is preserved